Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single‐Dose, Open‐Label, Randomized, Four‐Sequence, Four‐Period, Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability of Single Doses of Clobazam Oral Soluble Film (COSF) with Clobazam Tablets (CTAB)

Next Previous
X
Search
Trial Profile

A Single‐Dose, Open‐Label, Randomized, Four‐Sequence, Four‐Period, Crossover Study to Compare the Pharmacokinetics, Safety and Tolerability of Single Doses of Clobazam Oral Soluble Film (COSF) with Clobazam Tablets (CTAB)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clobazam (Primary) ; Clobazam
  • Indications Lennox-Gastaut syndrome
  • Focus Pharmacokinetics; Registrational
  • Sponsors Aquestive Therapeutics

    • Most Recent Events

    • 20 Dec 2018 According to an Aquestive Therapeutics media release, the data was presented at the American Epilepsy Society 2018 Annual Meeting in early December.
    • 02 Nov 2018 According to an Aquestive Therapeutics media release, the U.S. Food and Drug Administration (FDA) approved SYMPAZAN (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.
    • 24 Oct 2018 According to results published in the Epilepsia Journal, clobazam oral soluble film (COSF) at single doses of 10 and 20 mg was bioequivalent to clobazam tablets (CTAB) at equivalent doses for both clobazam and its active metabolite N-desmethylclobazam.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top